title: Second allogeneic transplantation for relapsed acute leukemia after initial allogeneic hematopoietic stem cell transplantation.
abstract: We retrospectively reviewed the medical records of 45 patients with relapsed acute leukemia after initial allogeneic hematopoietic stem cell transplantation (allo-HSCT). Among 45 patients, a total of 11 patients eventually underwent second allo-HSCT (HSCT-2). Median survival after relapse was 294 days (range, 135-942 days) for HSCT-2. Multivariate analysis showed significantly better survival for recipients of second allo-HSCT than for other patients (hazard ratio, 4.38; 95 % confidence interval, 1.45-13.2; P = 0.009). Although outcomes for patients with relapsed leukemia were generally poor, our results suggest that second HSCT could offer a survival advantage over other conventional salvage strategies.
authors.affiliation: Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo, 113-8677, Japan.
authors.forename: Ryo
authors.initials: R
authors.lastname: Hanajiri
authors.forename: Kazuteru
authors.initials: K
authors.lastname: Ohashi
authors.forename: Yuka
authors.initials: Y
authors.lastname: Hirashima
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Kakihana
authors.forename: Takeshi
authors.initials: T
authors.lastname: Kobayashi
authors.forename: Takuya
authors.initials: T
authors.lastname: Yamashita
authors.forename: Hisashi
authors.initials: H
authors.lastname: Sakamaki
authors.forename: Hideki
authors.initials: H
authors.lastname: Akiyama
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D007938:Leukemia / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D012086:Reoperation; D012189:Retrospective Studies; D016879:Salvage Therapy / Q000379:methods; D016019:Survival Analysis; D014184:Transplantation, Homologous; D016896:Treatment Outcome